Biomerica develops, manufactures, and sells in vitro diagnostic test kits designed to detect medical conditions, diseases, and food intolerances from blood, urine, nasal, and fecal samples. The company's product portfolio includes established immunoassay and ELISA tests, such as EZ Detect for colon disease screening and hp+detect for H. pylori detection, which are sold to clinical laboratories, hospitals, and point-of-care settings. Biomerica also develops inFoods IBS, a patented diagnostic test that identifies patient-specific food triggers to help manage irritable bowel syndrome. The company sells its diagnostic products primarily through a network of independent distributors across North America, Europe, Asia, and the Middle East, supplemented by an internal sales team. In addition to product sales, Biomerica provides contract development and manufacturing services to third-party life sciences and diagnostic companies. Biomerica's strategy focuses on expanding international distribution for hp+detect, broadening insurance reimbursement and physician adoption for inFoods IBS, and pursuing out-licensing partnerships to scale its diagnostic technologies across other therapeutic areas.